• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Thinking Pink: the Case for Femtech in 2020 and Beyond

Share:

January 8, 2020

In 2012, investments in female-specific health technology (femtech, as it has been coined) totaled $57M. By the close of 2019, they’re projected to reach $1B. That’s a 1651% increase in a mere seven years — and the numbers continue to climb.

The boom can be pinned to a multitude of causes, not least among them a growing (though still very much in the minority) number of female venture capitalists, and their interest in investing in female-driven solutions. But at the root of the phenomenon is something much more basic and fundamental than an uptick in female leadership: VCs are investing in femtech solutions simply because women need and want them.

It was a man’s world

Until very recently, medical research was carried out on the assumption that, with the exception of breast cancer, gynecology, and obstetrics, there is no difference between men and women’s healthcare. Not surprisingly, based on these assumptions, a meta-analysis of important medical trials conducted in the late part of the century found that participation numbers were highly skewed toward males, with women rarely making up more than one-third of trial populations.

As a result, many of the protocols and solutions targeted to manage chronic illness and other health concerns were developed based on the physiology of men — physiology that is now acknowledged to be significantly distinct from that of women.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

In the modern workforce, women freeze in offices that are controlled by temperature equations developed in the 1960s, based on the metabolism of men. In the same way, women have been woefully underserved by a healthcare system that services them with standards of care based on male physiology.

Until now. As healthcare innovators have recognized the distinct needs of females and the biases of former research trials, resources and solutions have proliferated to fill the gender gap in the delivery of healthcare. We talk about women’s health vs. general healthcare, but that’s really a false dichotomy. “General healthcare” is typically designed with men in mind, and allocating resources to women’s care isn’t taking away funding from men, but simply trying to right the scale.

Whatever women want, women should get

Women are the primary healthcare decision-makers in a household. They’re also the more likely of the two sexes to have healthcare, to go to the doctor, and to use tools geared toward their health and wellness. By offering femtech solutions to their female patient populations, healthcare providers are doing more than the necessary and important work of filling the gender gap — they’re engaging their constituency.

A positive experience with a health provider can bring a woman back to a health system for her pregnancy, for pediatric care, for her spouse’s care or her live-in mother. Targeting her experience is crucial for a health provider to build their customer base and establish brand loyalty.

And what do women want? The success of femtech should answer the question. They want convenient solutions, specifically, digital solutions that are personalized for their needs— needs that have been left out of the scope of “comprehensive” care even in our age of innovation, an age that we expect to be synonymous with inclusion and progress. Take Apple’s Healthkit, for example. In the 2014 release of the app, it was billed it as a “comprehensive” health tracking solution, yet it included no function for tracking female reproductive health (NB: the app has since been updated to include such a function).

Women are from Venus, Men are from Mars

Beyond redrawing the limits of “comprehensive” to actually fulfill its meaning, femtech is meeting the needs of women that don’t fall within the scope of general healthcare. It’s a both/and issue. General health protocols should be based on male and female physiology, and we also need tools to address the specific needs of females, whose unique physiology demands something outside the limits of general healthcare.

Pregnancy, menstruation, and menopause are just a few of the unique health events that solely affect women. And possibly because of their gender-selective nature, there’s been an implicit embargo on any conversation surrounding them. A history of shame and stigma around the “problems” femtech addresses has made the market all the more ripe for it, to make up for the years of sweeping female needs under the rug.

And women crave solutions that meet these needs. There’s a reason the “pink tax” is effective — women will pay more (though they shouldn’t need to) for products that complement their individual experiences, and — significantly for customer building and brand loyalty — they will patronize and return to the businesses that offer them these tailored products and experiences.

If health systems are going to retain and attract new customers, femtech is a critical starting place: it’s what women want.

Source: Hit Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Pediatric-Focused Mental Health Startup Brightline Scores $72M in Series B FundingPediatric-Focused Mental Health Startup Brightline Scores $72M in Series B Funding
  • TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas BioTrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio
  • Inari Medical Closes Acquisition of LimFlowInari Medical Closes Acquisition of LimFlow
  • Amnesty International Warns Against Google-Fitbit Merger Unless Human Rights are SafeguardedAmnesty International Warns Against Google-Fitbit Merger Unless Human Rights are Safeguarded
  • Alvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical CompanyAlvotech and Oaktree Acquisition Corp. II Announce Merger Agreement to Create a Leading Publicly-Traded Global Biopharmaceutical Company
  • Companies in the Multivitamin Capsules and Tablets Market Partner with Other Players to Improve Their Product Portfolio as Per the Business Research Company’s Multivitamin Capsules and Tablets Global Market Report 2022Companies in the Multivitamin Capsules and Tablets Market Partner with Other Players to Improve Their Product Portfolio as Per the Business Research Company’s Multivitamin Capsules and Tablets Global Market Report 2022
  • Biogen and Ginkgo Bioworks Partner to Redefine AAV-Based Vector ManufacturingBiogen and Ginkgo Bioworks Partner to Redefine AAV-Based Vector Manufacturing
  • Banner Health Taps Innovaccer’s Data Activation Platform to Power Digital TransformationBanner Health Taps Innovaccer’s Data Activation Platform to Power Digital Transformation

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications